Mechanistically, CENPT increases the catalytic activity of GCLC by directly binding to GCLC 213-424aa competitively with glutamate-cysteine ligase modifier subunit (GCLM), consequently induces the GSH synthesis
& Du, H
It is used to treat and prevent vitamin deficiencies in patients unable to take oral medications
When to stop Stop the protocol and contact your provider if you experience persistent redness or swelling at injection sites beyond 72 hours, fever, or any systemic symptom that does not correlate with the expected mild post-injection reaction
Pharmacotherapy Synergy: Metformin, GLP-1/GIP Agents, and Lisdexamfetamine Metformin : reduces hepatic gluconeogenesis, improves hepatic insulin sensitivity, modest weight loss, beneficial in PCOS and MASLD risk (Rubio et al., 2020) Tirzepatide (GIP/GLP-1) : significant satiety, delayed gastric emptying, improved insulin secretion in a glucose-dependent manner, glucagon reduction, weight loss, improved A1C/triglycerides/inflammation (Frias et al., 2021) Contraception considerations : incretin agents may delay gastric emptying
